GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (STU:ILU) » Definitions » Loans Receivable

Illumina (STU:ILU) Loans Receivable : €0 Mil (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Illumina Loans Receivable?

Illumina's Loans Receivable for the quarter that ended in Dec. 2023 was €0 Mil.


Illumina Loans Receivable Historical Data

The historical data trend for Illumina's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Loans Receivable Chart

Illumina Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Illumina Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Illumina Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Illumina Loans Receivable Related Terms

Thank you for viewing the detailed overview of Illumina's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Illumina (STU:ILU) Business Description

Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates about 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (about 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Illumina (STU:ILU) Headlines

No Headlines